Rubinsak Lisa A, Terplan Mishka, Martin Caitlin E, Fields Emma C, McGuire William P, Temkin Sarah M
Virginia Commonwealth University Health System, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, United States of America.
Virginia Commonwealth University Health System, Department of Obstetrics and Gynecology, United States of America.
Gynecol Oncol Rep. 2019 Mar 27;28:116-119. doi: 10.1016/j.gore.2019.03.016. eCollection 2019 May.
The purpose of this study was to identify the prevalence of substance use disorder and its association with adherence to treatment and survival in locally advanced cervical cancer patients treated with primary radiation therapy. This is a retrospective case series of locally advanced cervical cancer patients with substance use disorder in a single academic institution treated with radiation therapy between 2005 and 2016. Substance use disorder was identified through chart review. Those with substance use disorder were compared to those without in regards to demographics, Charlson comorbidity index, treatment details and outcomes. Of the 129 patients with locally advanced cervical cancer, 16 (12.4%) were identified as having substance use disorder. Patients with substance use disorder were younger (42.1 years vs 51.5 years, p = .013) and more likely to be smokers (81.3% vs 42.5%, p = .004). The majority of patients with substance use disorder received concurrent chemotherapy (93.8%) and brachytherapy in addition to external beam radiation therapy (81.3%). There was no significant difference in days to completion of radiation therapy between patients with and without substance use disorder. Radiation dose received, toxicities and survival were similar between groups. Among cervical cancer patients receiving treatment with radiation therapy, substance use disorder was not associated with poorer adherence, longer radiation treatment times or a difference in total dose of radiation received. Our experience demonstrates that patients with substance use disorder are able to adhere to complex, multimodal treatment plans resulting in similar cancer specific outcomes compared to patients without substance use disorder.
本研究的目的是确定物质使用障碍的患病率及其与接受原发性放射治疗的局部晚期宫颈癌患者治疗依从性和生存率的关联。这是一项回顾性病例系列研究,研究对象为2005年至2016年间在单一学术机构接受放射治疗的患有物质使用障碍的局部晚期宫颈癌患者。通过病历审查确定物质使用障碍。将患有物质使用障碍的患者与未患该障碍的患者在人口统计学、查尔森合并症指数、治疗细节和结局方面进行比较。在129例局部晚期宫颈癌患者中,16例(12.4%)被确定患有物质使用障碍。患有物质使用障碍的患者更年轻(42.1岁对51.5岁,p = 0.013),且更有可能是吸烟者(81.3%对42.5%,p = 0.004)。大多数患有物质使用障碍的患者除接受外照射放疗外,还接受了同步化疗(93.8%)和近距离放疗(81.3%)。患有和未患有物质使用障碍的患者完成放疗的天数没有显著差异。两组之间接受的放射剂量、毒性和生存率相似。在接受放射治疗的宫颈癌患者中,物质使用障碍与较差的依从性、更长的放射治疗时间或所接受的总放射剂量差异无关。我们的经验表明,与没有物质使用障碍的患者相比,患有物质使用障碍的患者能够坚持复杂的多模式治疗计划,从而获得相似的癌症特异性结局。